140 related articles for article (PubMed ID: 33262268)
1. Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET.
Hope TA
J Nucl Med; 2020 Dec; 61(12):1764. PubMed ID: 33262268
[No Abstract] [Full Text] [Related]
2. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.
Wild D; Mäcke HR; Waser B; Reubi JC; Ginj M; Rasch H; Müller-Brand J; Hofmann M
Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):724. PubMed ID: 15551131
[No Abstract] [Full Text] [Related]
3. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.
Werner RA; Solnes LB; Javadi MS; Weich A; Gorin MA; Pienta KJ; Higuchi T; Buck AK; Pomper MG; Rowe SP; Lapa C
J Nucl Med; 2018 Jul; 59(7):1085-1091. PubMed ID: 29572257
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor PET imaging with Gallium-68 labeled peptides.
Win Z; Al-Nahhas A; Rubello D; Gross MD
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):244-50. PubMed ID: 17464267
[TBL] [Abstract][Full Text] [Related]
5. What can gallium-68 PET add to receptor and molecular imaging?
Al-Nahhas A; Win Z; Szyszko T; Singh A; Khan S; Rubello D
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1897-901. PubMed ID: 17713764
[No Abstract] [Full Text] [Related]
6. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis.
Treglia G; Tamburello A; Giovanella L
Hormones (Athens); 2017 Oct; 16(4):362-372. PubMed ID: 29518756
[TBL] [Abstract][Full Text] [Related]
7. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
8. Initial staging of lymphoma with octreotide and other receptor imaging agents.
Ferone D; Semino C; Boschetti M; Cascini GL; Minuto F; Lastoria S
Semin Nucl Med; 2005 Jul; 35(3):176-85. PubMed ID: 16098291
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
10. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTANOC somatostatin receptor PET-CT imaging in multiple myeloma.
Sharma P; Dhull VS; Suman S; Bal C; Malhotra A; Kumar R
Clin Nucl Med; 2014 Apr; 39(4):374-5. PubMed ID: 23640227
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques.
Rinne P; Hellberg S; Kiugel M; Virta J; Li XG; Käkelä M; Helariutta K; Luoto P; Liljenbäck H; Hakovirta H; Gardberg M; Airaksinen AJ; Knuuti J; Saraste A; Roivainen A
Mol Imaging Biol; 2016 Feb; 18(1):99-108. PubMed ID: 26122428
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
14. Receptor PET/CT imaging of neuroendocrine tumors.
Baum RP; Prasad V; Hommann M; Hörsch D
Recent Results Cancer Res; 2008; 170():225-42. PubMed ID: 18019630
[No Abstract] [Full Text] [Related]
15. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma.
Sollini M; Taralli S; Milella M; Erba PA; Rubagotti S; Fraternali A; Roncali M; Moscarella E; Perotti G; Rufini V; Versari A
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1507-11. PubMed ID: 26446694
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Lee DY; Kim YI
Clin Nucl Med; 2019 Oct; 44(10):777-783. PubMed ID: 31283601
[TBL] [Abstract][Full Text] [Related]
19. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
20. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
Johnbeck CB; Knigge U; Kjær A
Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
